Valerio Therapeutics Revenue
Pharmaceutical Manufacturing • 
Paris, Île-de-France, France • 51-100 Employees
Valerio Therapeutics revenue & valuation
| Annual revenue | $1,751,477 |
| Revenue per employee | $35,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $5,700,000 |
| Total funding | No funding |
Key Contacts at Valerio Therapeutics
Geetha Godlove
Senior Director Regulatory Affairs And Medical Writing
Lucile Dez
Hr And Administrative Director
Shefali Agarwal
Ceo And President
Mégane Debiais
Chemistry Director
David Carp
Associate Director - Finance
Fetta Mazed
Associate Director, Antibody
Dominique Costantini
Ceo
Company overview
| Headquarters | 49 Boulevard du Général Martial Valin, Paris, 75015, FR |
| Phone number | +3301703833 |
| Website | |
| NAICS | 3254 |
| Keywords | Licensing, Partnering, Cancer, M&A, Oncology, Epigenetics, DDR, Translational Research, Dna Repair, Hdac, Dna Damage Response, Oligonucleotide, Dna Decoy |
| Founded | 2014 |
| Employees | 51-100 |
| Socials |
Valerio Therapeutics Email Formats
Valerio Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@valeriotx.com), used 51.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@valeriotx.com | 51.6% |
{first initial}.{last name} | j.doe@valeriotx.com | 48.4% |
About Valerio Therapeutics
Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners. The Company's portfolio is based on platON™, Valerio Therapeutic's decoy oligonucleotide platform. PlatON™ is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides. The Company's portfolio includes: - AsiDNA™, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNA™ is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy. - A new family of compounds are positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. VIO-01, is currently being optimized in a preclinical phase. The Company is convinced of the significant therapeutic potential of its technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer and inflammatory disease treatments.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Valerio Therapeutics has 27 employees across 12 departments.
Departments
Number of employees
Funding Data
Valerio Therapeutics has never raised funding before.
Valerio Therapeutics Tech Stack
Discover the technologies and tools that power Valerio Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Security
Analytics
Video players
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Programming languages
Blogs
JavaScript libraries
United Kingdom
Czechia
Spain
Frequently asked questions
4.8
40,000 users
